GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Cirrhosis Liver/Cirrhosis and Extrahepatic organ failures
62

Cirrhosis and Extrahepatic organ failures

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated December 1, 2025

Cirrhosis is a severe liver condition that can progress to acute-on-chronic liver failure (ACLF), a life-threatening state characterized by organ failures beyond the liver, known as extrahepatic organ failures (EHOFs). EHOFs commonly affect the kidneys, brain, respiratory system, or circulatory system. A recent study analyzed hospital admissions data from Germany, France, Italy, and Denmark (2005–2020 for Germany; 2017–2020 for others) to assess the burden of cirrhosis combined with EHOFs.

The study revealed that, out of 1,599,680 hospital admissions for cirrhosis across the four countries, 329,093 (20.6%) involved at least one EHOF. Kidney failure was the most common EHOF (52.9%), followed by respiratory failure (41.2%). Although the overall number of hospital admissions for cirrhosis decreased over time, the proportion of admissions with EHOFs increased from 19.9% to 21.5%. Patients with EHOFs had a significantly higher in-hospital mortality rate (29.2%) compared to those with cirrhosis alone (7.9%).

EHOFs in cirrhosis patients accounted for 44.9% of healthcare claims, highlighting the substantial economic strain on healthcare systems. These findings emphasize the urgent need for stakeholders to implement strategies to reduce the burden of EHOFs in cirrhosis patients, improving outcomes and alleviating healthcare costs.

Related Q&A

63

VOCAL-Penn score

The VOCAL-Penn score (VPS) is a medical risk prediction tool developed in 2021 to estimate postoperative mortality and decompensation risk in patients with cirrhosis undergoing surgical procedures. It...

64

Adrenal Dysfunction and HPA Axis Impairment in Decompensated Cirrhosis

Adrenal dysfunction (AD) and hypothalamic–pituitary–adrenal (HPA) axis impairment are important yet poorly understood phenomena in patients with decompensated cirrhosis, particularly in stable, non-hospitalized individuals. The study you referenced...

65

Incidence and Clinical Significance of Recompensation After HCV Cure

The incidence and clinical significance of recompensation after hepatitis C virus (HCV) cure in patients with decompensated cirrhosis have been a focus of detailed analysis. Here is a...

66

Early Hepatic Encephalopathy After TIPS Is Associated With Reduced Survival

Yes, early hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) placement is strongly associated with reduced survival. This conclusion is supported by a large multicenter analysis involving...

67

AGA Clinical Practice Update on Ascites, Volume Overload, and Hyponatremia in Cirrhosis

The American Gastroenterological Association (AGA) Clinical Practice Update on Ascites, Volume Overload, and Hyponatremia in Cirrhosis provides evidence-based guidance on the management of these complications in patients with...

68

Circulating microbiome profiling in transjugular intrahepatic portosystemic shunt patients: 16S rRNA vs. shotgun sequencing

The study focused on comparing the performance of 16S rRNA sequencing and shotgun metagenomic sequencing for profiling the circulating microbiome in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS)...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer